<DOC>
	<DOCNO>NCT00656461</DOCNO>
	<brief_summary>This open-label study determine high dose MKC-1 may administer daily continuous basis patient advance refractory solid tumor .</brief_summary>
	<brief_title>Phase 1 Study MKC-1 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have histologically confirm malignancy metastatic unresectable standard curative measure exist longer effective . Age great equal 18 year . ECOG performance status ≤1 ANC great equal 1,500/mm3 ; Platelets great equal 100,000/mm3 creatinine ≤1.5 time institutional upper limit normal ( ULN ) T Bili within normal limit ; AST ALT less equal 2.5 time ULN ; albumin great equal 3.0 g/dL measurable disease RECIST , radiographically evaluable disease , detectable disease woman childbearing potential men must agree use adequate contraception Ability understand willingness sign write informed consent document . Have previously receive MKC1 . Have receive radiation great 25 % bone marrow . Have anticancer therapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier . Are concurrently receive investigational agent study . Have know brain metastasis Have condition impairs ability swallow retain MKC1 capsule . Uncontrolled intercurrent illness Are pregnant breastfeed HIVpositive patient Patients uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Advanced cancer</keyword>
</DOC>